1. ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells
- Author
-
Ying-Li Wu, Yu-Sheng Wei, Xiao-Na Zhu, Junke Zheng, Shao-Ming Shen, Di Zhu, Guo-Qiang Chen, Meng-Di Liu, Li Xia, Meng-Kai Ge, Yun Yu, Hui-Lin Zhang, Ping He, Meng Zhao, Shuo Yang, Yi-Lian Pan, and Qian Yang
- Subjects
Hematopoiesis and Stem Cells ,Immunology ,Cell Cycle Proteins ,Nerve Tissue Proteins ,Biology ,Biochemistry ,Mice ,Myelogenous ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,medicine ,Animals ,Psychological repression ,Cells, Cultured ,Gene Expression Regulation, Leukemic ,Regeneration (biology) ,Nuclear Proteins ,Cell Biology ,Hematology ,Hematopoietic Stem Cells ,medicine.disease ,Cell biology ,Haematopoiesis ,Leukemia ,Phosphoprotein ,Neoplastic Stem Cells ,Tumor Suppressor Protein p53 ,Stem cell ,Tyrosine kinase - Abstract
Proper regulation of p53 signaling is critical for the maintenance of hematopoietic stem cells (HSCs) and leukemic stem cells (LSCs). The hematopoietic cell–specific mechanisms regulating p53 activity remain largely unknown. Here, we demonstrate that conditional deletion of acidic leucine-rich nuclear phosphoprotein 32B (ANP32B) in hematopoietic cells impairs repopulation capacity and postinjury regeneration of HSCs. Mechanistically, ANP32B forms a repressive complex with p53 and thus inhibits the transcriptional activity of p53 in hematopoietic cells, and p53 deletion rescues the functional defect in Anp32b-deficient HSCs. Of great interest, ANP32B is highly expressed in leukemic cells from patients with chronic myelogenous leukemia (CML). Anp32b deletion enhances p53 transcriptional activity to impair LSC function in a murine CML model and exhibits synergistic therapeutic effects with tyrosine kinase inhibitors in inhibiting CML propagation. In summary, our findings provide a novel strategy to enhance p53 activity in LSCs by inhibiting ANP32B and identify ANP32B as a potential therapeutic target in treating CML.
- Published
- 2021
- Full Text
- View/download PDF